Literature DB >> 26432954

Animal models for diabetes: Understanding the pathogenesis and finding new treatments.

Aileen King1, James Bowe2.   

Abstract

Diabetes mellitus is a lifelong, metabolic disease that is characterised by an inability to maintain normal glucose homeostasis. There are several different forms of diabetes, however the two most common are Type 1 and Type 2 diabetes. Type 1 diabetes is caused by the autoimmune destruction of pancreatic beta cells and a subsequent lack of insulin production, whilst Type 2 diabetes is due to a combination of both insulin resistance and an inability of the beta cells to compensate adequately with increased insulin release. Animal models are increasingly being used to elucidate the mechanisms underlying both Type 1 and Type 2 diabetes as well as to identify and refine novel treatments. However, a wide range of different animal models are currently in use. The majority of these models are suited to addressing certain specific aspects of diabetes research, but may be of little use in other studies. All have pros and cons, and selecting an appropriate model for addressing a specific question is not always a trivial task and will influence the study results and their interpretation. Thus, as the number of available animal models increases it is important to consider the potential roles of these models in the many different aspects of diabetes research. This review gathers information on the currently used experimental animal models of both Type 1 and Type 2 diabetes and evaluates their advantages and disadvantages for research purposes and details the factors that should be taken into account in their use.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Animal models; Type 1 diabetes; Type 2 diabetes

Mesh:

Substances:

Year:  2015        PMID: 26432954     DOI: 10.1016/j.bcp.2015.08.108

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  35 in total

Review 1.  Effects of Type II Diabetes Mellitus on Tendon Homeostasis and Healing.

Authors:  Anne E C Nichols; Irvin Oh; Alayna E Loiselle
Journal:  J Orthop Res       Date:  2019-06-24       Impact factor: 3.494

Review 2.  Considerations and guidelines for mouse metabolic phenotyping in diabetes research.

Authors:  Thierry Alquier; Vincent Poitout
Journal:  Diabetologia       Date:  2017-11-16       Impact factor: 10.122

Review 3.  The promise and reality of therapeutic discovery from large cohorts.

Authors:  Eugene Melamud; D Leland Taylor; Anurag Sethi; Madeleine Cule; Anastasia Baryshnikova; Danish Saleheen; Nick van Bruggen; Garret A FitzGerald
Journal:  J Clin Invest       Date:  2020-02-03       Impact factor: 14.808

Review 4.  Links between lower urinary tract symptoms, intermittent hypoxia and diabetes: Causes or cures?

Authors:  Lisa L Abler; Chad M Vezina
Journal:  Respir Physiol Neurobiol       Date:  2017-09-18       Impact factor: 1.931

5.  Premise for Standardized Sepsis Models.

Authors:  Daniel G Remick; Alfred Ayala; Irshad H Chaudry; Craig M Coopersmith; Clifford Deutschman; Judith Hellman; Lyle Moldawer; Marcin F Osuchowski
Journal:  Shock       Date:  2019-01       Impact factor: 3.454

Review 6.  Sex differences in diabetes and kidney disease: mechanisms and consequences.

Authors:  Blythe D Shepard
Journal:  Am J Physiol Renal Physiol       Date:  2019-06-26

Review 7.  Challenges in vascular tissue engineering for diabetic patients.

Authors:  Jhilmil Dhulekar; Agneta Simionescu
Journal:  Acta Biomater       Date:  2018-02-01       Impact factor: 8.947

8.  Topical Naltrexone Is a Safe and Effective Alternative to Standard Treatment of Diabetic Wounds.

Authors:  Patricia J McLaughlin; Jarrett D Cain; Michelle B Titunick; Joseph W Sassani; Ian S Zagon
Journal:  Adv Wound Care (New Rochelle)       Date:  2017-09-01       Impact factor: 4.730

9.  A Dual Reporter EndoC-βH1 Human β-Cell Line for Efficient Quantification of Calcium Flux and Insulin Secretion.

Authors:  Fabian L Cardenas-Diaz; Karla F Leavens; Siddharth Kishore; Catherine Osorio-Quintero; Yi-Ju Chen; Ben Z Stanger; Pei Wang; Deborah French; Paul Gadue
Journal:  Endocrinology       Date:  2020-02-01       Impact factor: 4.736

10.  HWL-088, a new potent free fatty acid receptor 1 (FFAR1) agonist, improves glucolipid metabolism and acts additively with metformin in ob/ob diabetic mice.

Authors:  Yueming Chen; Qiang Ren; Zongtao Zhou; Liming Deng; Lijun Hu; Luyong Zhang; Zheng Li
Journal:  Br J Pharmacol       Date:  2020-02-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.